secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2026-08-05T10:31:36+00:00
Accession:  0001601830-26-000097
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Pharmaceuticals Reports Q2 2026 Results; Genentech Options First Neuroscience Target
--------------------------------------------------------------------------------

- Genentech exercised first Validated Target Option under neuroscience collaboration, advancing a previously unexplored target into early discovery program.
- REC-4881 Phase 2 FAP data to be presented at CGA-IGC Presidential Plenary in November 2026; FDA discussions initiated for registrational path.
- REC-7735 IND cleared; Phase 1/2 ZINNIA trial for PIK3CA H1047R-mutant solid tumors to start in 2H26.
- Revenue was $7.7M in Q2 2026, down from $19.2M in Q2 2025; net loss improved to $131.0M from $171.9M.
- Cash operating expense guidance reduced to <$375M for 2026; cash runway extends into early 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/0001601830-26-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/rxrx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001601830-26-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer